{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pediatric+Low-grade+Gliomas&page=2", "query": { "condition": "Pediatric Low-grade Gliomas", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 36, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pediatric+Low-grade+Gliomas&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pediatric+Low-grade+Gliomas&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-30T13:11:35.146Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05503797", "title": "A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer Harboring BRAF Alterations", "HGG", "LGG", "Solid Tumors" ], "interventions": [ { "name": "Plixorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fore Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": null, "sex": "ALL", "summary": "8 Years and older" }, "enrollment_count": 254, "start_date": "2023-02-21", "completion_date": "2028-12-28", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-09-30T13:11:35.146Z", "location_count": 30, "location_summary": "Beverly Hills, California • San Francisco, California • Westwood, Los Angeles, California + 23 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Westwood, Los Angeles", "state": "California" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05503797" }, { "nct_id": "NCT03194906", "title": "Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioma of Brain", "Craniopharyngioma", "Ependymoma", "Germ Cell Tumor" ], "interventions": [ { "name": "Memantine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Cognitive Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "6 Years to 21 Years" }, "enrollment_count": 41, "start_date": "2017-11-07", "completion_date": "2023-06-28", "has_results": true, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-09-30T13:11:35.146Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03194906" }, { "nct_id": "NCT06712875", "title": "MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Low Grade Glioma", "High Grade Glioma" ], "interventions": [ { "name": "Trametinib and Nivolumab", "type": "DRUG" }, { "name": "Dabrafenib, trametinib, nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ann & Robert H Lurie Children's Hospital of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "26 Years", "sex": "ALL", "summary": "1 Year to 26 Years" }, "enrollment_count": 27, "start_date": "2025-04-01", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-09-30T13:11:35.146Z", "location_count": 3, "location_summary": "Washington D.C., District of Columbia • Chicago, Illinois • New York, New York", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06712875" }, { "nct_id": "NCT01497860", "title": "Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Low-grade Glioma" ], "interventions": [ { "name": "Vinorelbine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eugene Hwang", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": 13, "start_date": "2011-07", "completion_date": "2017-07", "has_results": true, "last_update_posted_date": "2019-05-20", "last_synced_at": "2026-09-30T13:11:35.146Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Rochester, Minnesota", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01497860" }, { "nct_id": "NCT06104488", "title": "A Study of Avutometinib for People With Solid Tumor Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory Cancer", "CNS Tumors", "CNS Tumor, Adult", "CNS Tumor, Childhood", "MAP Kinase Family Gene Mutation", "NF1", "Plexiform Neurofibroma", "Low-grade Glioma", "Optic Pathway Gliomas", "Neuroblastoma", "Primary Brain Tumor", "Solid Tumor", "Solid Tumor, Adult", "Solid Carcinoma", "Central Nervous System Tumor" ], "interventions": [ { "name": "Avutometinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "3 Years to 30 Years" }, "enrollment_count": 3, "start_date": "2023-10-20", "completion_date": "2029-10-20", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-09-30T13:11:35.146Z", "location_count": 2, "location_summary": "Atlanta, Georgia • New York, New York", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06104488" }, { "nct_id": "NCT00363272", "title": "Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Burkitt Lymphoma", "Childhood Central Nervous System Germ Cell Tumor", "Childhood Choroid Plexus Tumor", "Childhood Craniopharyngioma", "Childhood Grade I Meningioma", "Childhood Grade II Meningioma", "Childhood Grade III Meningioma", "Childhood High-grade Cerebral Astrocytoma", "Childhood Infratentorial Ependymoma", "Childhood Low-grade Cerebral Astrocytoma", "Childhood Spinal Cord Neoplasm", "Childhood Supratentorial Ependymoma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Brain Tumor", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "ispinesib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 30, "start_date": "2006-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-16", "last_synced_at": "2026-09-30T13:11:35.146Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00363272" }, { "nct_id": "NCT03213665", "title": "Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Ann Arbor Stage III Hodgkin Lymphoma", "Ann Arbor Stage III Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Hodgkin Lymphoma", "Ann Arbor Stage IV Non-Hodgkin Lymphoma", "Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Low Grade Glioma", "Recurrent Ependymoma", "Recurrent Ewing Sarcoma", "Recurrent Glioma", "Recurrent Hepatoblastoma", "Recurrent Hodgkin Lymphoma", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Glioma", "Recurrent Malignant Solid Neoplasm", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Peripheral Primitive Neuroectodermal Tumor", "Recurrent Primary Central Nervous System Neoplasm", "Recurrent Rhabdoid Tumor", "Recurrent Rhabdomyosarcoma", "Recurrent Soft Tissue Sarcoma", "Refractory Hodgkin Lymphoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Glioma", "Refractory Malignant Solid Neoplasm", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Peripheral Primitive Neuroectodermal Tumor", "Refractory Rhabdoid Tumor", "Refractory Soft Tissue Sarcoma", "Rhabdoid Tumor", "Stage III Soft Tissue Sarcoma AJCC v7", "Stage IV Soft Tissue Sarcoma AJCC v7", "Wilms Tumor" ], "interventions": [ { "name": "Tazemetostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 20, "start_date": "2017-11-13", "completion_date": "2024-12-31", "has_results": true, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-30T13:11:35.146Z", "location_count": 115, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 91 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03213665" }, { "nct_id": "NCT00005952", "title": "Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Childhood Germ Cell Tumor", "Head and Neck Cancer", "Kidney Cancer", "Neuroblastoma", "Ovarian Cancer", "Sarcoma", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": 30, "start_date": "2000-08", "completion_date": "2005-11", "has_results": false, "last_update_posted_date": "2013-06-20", "last_synced_at": "2026-09-30T13:11:35.146Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005952" }, { "nct_id": "NCT01837862", "title": "A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pilomyxoid Astrocytoma", "Pilocytic Astrocytoma", "Glioma, Astrocytic", "Optic Nerve Glioma", "Pleomorphic Xanthoastrocytoma", "Glioblastoma Multiforme", "Anaplastic Astrocytoma", "Gliosarcoma", "Diffuse Intrinsic Pontine Glioma", "DIPG", "Low-grade Glioma", "Brainstem Glioma" ], "interventions": [ { "name": "Mebendazole", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Julie Krystal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 10, "start_date": "2013-10-22", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-09-30T13:11:35.146Z", "location_count": 1, "location_summary": "New Hyde Park, New York", "locations": [ { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01837862" }, { "nct_id": "NCT01130077", "title": "A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction with Poly-ICLC in Pediatric Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Newly Diagnosed Pediatric Pontine Glioma", "Newly Diagnosed Pediatric High Grade Glioma", "Recurrent Pediatric High Grade Glioma", "Recurrent Pediatric Low Grade Glioma" ], "interventions": [ { "name": "HLA-A2 restricted glioma antigen peptides vaccine", "type": "BIOLOGICAL" }, { "name": "Poly-ICLC", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "James Felker", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 60, "start_date": "2009-02", "completion_date": "2024-11-01", "has_results": false, "last_update_posted_date": "2024-12-06", "last_synced_at": "2026-09-30T13:11:35.146Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01130077" } ] }